# SUPPLEMENTARY DIGITAL MATERIAL 8

Detailed forest-plot regarding new technologies effect on activity after stroke

Supplementary Table XXXII.—Forest-plot regarding the effect of new-technologies on activity in patients with subacute stroke.

	Exp	eriment	al	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.13.1 Virtual reality									
Aprile et al., 2020	6.04	8.547	91	6.7	4.84	99	5.3%	-0.10 [-0.38, 0.19]	+
Brunner et al., 2017		12.01	57		11.83	55	4.8%	-0.06 [-0.43, 0.31]	+
Choi et al., 2014	12.6	5.7	10	15.3	7.2	10	2.4%	-0.40 [-1.29, 0.49]	<del></del>
da Silva Cameirao et al., 2011		10.31	8		11.05	8	1.8%	1.29 [0.18, 2.40]	
Kang et al., 2009		13.54	8		11.92	8	2.0%	0.87 [-0.17, 1.91]	<del> </del>
Kim et al., 2011		16.25	15		12.17	13	2.9%	0.03 [-0.72, 0.77]	+
Kim et al., 2018	8.4	8.68	11		10.35	8	2.3%	-0.12 [-1.03, 0.79]	
Kiper et al., 2011		14.59	40		12.63	40	4.4%	0.80 [0.34, 1.25]	-
Kiper et al., 2018		12.75	68		12.26	68	5.0%	0.36 [0.03, 0.70]	<u>.</u>
Kong et al., 2014		12.34	33		11.76	34	4.2%	0.20 [-0.28, 0.68]	<del> </del>
Kong et al., 2016		12.34	33		11.76	34	4.2%	0.20 [-0.28, 0.68]	_
Kwon et al., 2012	24.69	14.9	13			13	2.8%	0.23 [-0.54, 1.01]	
Laffont et al., 2020	15.7	16.3	25	7.4	12.2	26	3.8%	0.57 [0.01, 1.13]	-
Piron et al., 2007		19.37	25		18.51	13	3.2%	0.47 [-0.21, 1.15]	<del> </del>
Rogers et al., 2019	17.3	8.6	10	8.4	5.3	11	2.2%	1.21 [0.26, 2.16]	
Saposnik et al., 2010	8.6	3.9	9	12	4.18	9	2.2%	-0.80 [-1.77, 0.17]	
		10.62	59	8.9	9.39	62	4.9%		
Saposnik et al., 2016	11.3	10.62	9	6.3	5.67	7	2.0%	-0.13 [-0.49, 0.23]	1
Shin et al., 2014								0.53 [-0.48, 1.54]	
Standen et al., 2017	3.17	8.34	9	1.17	3.69	9	2.3%	0.30 [-0.63, 1.23]	
Turkbey et al., 2017	13.7	7.53	10	4.78	7.88	9	2.1%	1.11 [0.12, 2.09]	
Yin et al., 2014 Subtotal (95% CI)	18.37	20	11 <b>554</b>	17	21	12 <b>548</b>	2.7% <b>67.7%</b>	0.06 [-0.75, 0.88] 0.25 [0.07, 0.44]	
Test for overall effect: Z = 2.66 (I	2 = 0.008	)							
Aisen et al., 1997	25.6	7.23	10	25.7	12.25	10	2.4%	-0.01 [-0.89, 0.87]	+
Dehem et al., 2019	6.5	9.14	15	3.1	7.26	17	3.1%	0.40 [-0.30, 1.11]	<del> </del>
Hesse et al., 2014	9.2	10.8	25		10.76	25	3.8%	-0.35 [-0.91, 0.21]	<del>-</del>
Lum et al., 2006	3.1	1.4	10	3.2	1.4	6	2.0%	-0.07 [-1.08, 0.94]	<del></del>
Masiero et al., 2007	32.76	7.2	17	25.5	10.5	18	3.2%	0.78 [0.09, 1.47]	<del></del>
Rabadi et al., 2008	-0.59	7.33	10	3.94	3.2	10	2.3%	-0.77 [-1.68, 0.15]	<del></del>
Tomic et al., 2017	14.1	7.9	13	6.7	7.8	13	2.7%	0.91 [0.10, 1.73]	<del></del>
Villafane et al., 2018	22.8	2.4	16	21.6	2.4	16	3.1%	0.49 [-0.22, 1.19]	<del> </del>
Volpe et al., 2000	25	3.5	30	19.5	3.5	26	3.6%	1.55 [0.95, 2.15]	<del>-</del>
Subtotal (95% CI)		0.0	146	10.0	0.0	141	26.3%	0.36 [-0.13, 0.85]	<b>♦</b>
Heterogeneity: Tau $^2$ = 0.41; Chi $^2$ Test for overall effect: Z = 1.43 (I		df = 8 (F	P = 0.0	001); l²:	= 75%				
1.13.3 Telerehabilitation									
Chumbler et al., 2012	0.2	6.147	24	0.6	7.622	19	3.6%	-0.06 [-0.66, 0.54]	+
Duncan et al., 1998	13	5.16	10	13.3	5.27	10	2.4%	-0.06 [-0.93, 0.82]	<del>_</del>
Duncan et al., 1990 Subtotal (95% CI)	0.36	0.1	44 34	-1.42	1.34	49 <b>29</b>	6.0%	Not estimable -0.06 [-0.55, 0.44]	•
Heterogeneity: Tau² = 0.00; Chi² Test for overall effect: Z = 0.22 (I		if=1 (P		); I² = 09	6				
Total (95% CI)			734			712	100.0%	0.28 [0.10, 0.45]	
Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup>	= 74.32	df= 31		00011-1	= 58%		.00.070	0.20 [0.10, 0.43]	<u> </u>
Test for overall effect: Z = 3.07 (I Test for subgroup differences: (	P = 0.002	)							-10 -5 0 5 10 Favours [control] Favours [experimental]


# Supplementary Table XXXIII.—Forest-plot regarding the effect of new-technologies on activity in patients with chronic stroke.

	Exp	eriment			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
I.14.1 Virtual reality									
Askin et al., 2018	1.75	13.3	18	0	7.81	20	3.2%	0.16 [-0.48, 0.80]	<del></del>
Broeren et al., 2008	2.8	10	11	0.4	10.56	11	1.9%	0.22 [-0.61, 1.06]	<del></del>
3yl et al., 2013 (a)	1.8	8.32	5	6.5	10.3	3	0.6%	-0.45 [-1.92, 1.01]	<del></del>
3yl et al., 2013 (b)	-0.2	11.25	5	6.5	10.3	3	0.6%	-0.53 [-2.01, 0.95]	<del></del>
Chen et al., 2015 (a)	4.9	12	8	1.5	7.25	8	1.3%	0.32 [-0.66, 1.31]	<del></del>
Chen et al., 2015 (b)	3.1	13.12	8	1.5	7.25	8	1.4%	0.14 [-0.84, 1.12]	<del></del>
Crosbie et al., 2012	0.6	4.93	9	2.9	11.72	9	1.5%	-0.24 [-1.17, 0.68]	<del></del>
Ouff et al., 2012	0.47	0.36	11	0.54	0.28	10	1.8%	-0.21 [-1.07, 0.65]	<del></del>
ivon et al., 2015	-0.3	14.64	20	8.3	14.75	21	3.3%	-0.57 [-1.20, 0.05]	<del></del>
lousman et al., 2009	0.1	0.4	15	0.1	0.7	16	2.6%	0.00 [-0.70, 0.70]	
lung et al., 2019	0.085	0.41	17	0.07	0.72	16	2.8%	0.03 [-0.66, 0.71]	
n et al., 2012	26.35	32.09	11	3.43	7.67	.8	1.4%	0.87 [-0.09, 1.83]	<del> </del>
ang et al., 2005	4	4.84	5	-1.6	5.91	5	0.7%	0.94 [-0.41, 2.28]	
o et al., 2012	8.5	7.7	15	2	3.29	14	2.1%	1.05 [0.27, 1.84]	<del></del>
(im et al., 2012	1.5	10.51	10	0.28	5.06	10	1.7%	0.14 [-0.74, 1.02]	
(iper et al., 2014	15.7	17.78	24	8	14.83	21	3.7%	0.46 [-0.13, 1.05]	
Cottink et al., 2014	3.9	4.9	8	5	5.1	10	1.5%	-0.21 [-1.14, 0.72]	
	8.71	9.01	7	4.81	7.16	7	1.1%		
ee et al., 2013			13		10.48	13		0.45 [-0.62, 1.51]	
Lee et al., 2016		10.47		2.54			2.2%	0.03 [-0.74, 0.80]	
evin et al., 2012	0.8	17.28	6		12.83	6 9	1.0%	-0.16 [-1.29, 0.98]	
lorouzi et al., 2019		14.66	9	-1.6	9.18		1.5%	0.14 [-0.79, 1.07]	
gun et al., 2019	8.34	4.78	33	1.25	3.89	32	0.000	Not estimable	
oh et al., 2019	3.4	4.9	17	3.5	7.2	14	2.6%	-0.02 [-0.72, 0.69]	
ark et al., 2019	4.3	5.9	12	4.8	5.9	12	2.0%	-0.08 [-0.88, 0.72]	
iron et al., 2010	5.6	7.22	27	4.7	9.07	20	3.9%	0.11 [-0.47, 0.69]	
Rand et al., 2017	11.7	11.42	11	. 9	12.61	10	1.8%	0.22 [-0.64, 1.08]	
Schuster-Amft et al., 2018	24.37	15.2	22	20.17	21.5	32	4.4%	0.22 [-0.33, 0.76]	<del></del>
3in et al., 2013	9.56	4.61	18	2.71	3.12	17		Not estimable	
hielbar et al., 2014	3.1	5.6	7	-3.5	8.01	7	1.0%	0.89 [-0.22, 2.01]	<del></del>
urolla et al., 2013		12.42	263	6.9	12.99	113	26.9%	0.06 [-0.17, 0.28]	<u>†</u>
Condervan et al., 2016	0.7	2.3	9	-0.6	2.9	8	1.4%	0.48 [-0.49, 1.44]	
Subtotal (95% CI)			603			444	82.1%	0.11 [-0.01, 0.24]	•
leterogeneity: Tau² = 0.00; est for overall effect: Z = 1.	78 (P = 0		= 28 (F	' = 0.76)	; I² = 0%	5			
.14.2 Robot-assisted ther	ару								
um et al., 2002	0.2	0.2	13	0.001	0.001	14		Not estimable	
Shin et al., 2016	10.3	2.7	24	3.5	1.4	22		Not estimable	
Volf et al., 2015	5.1	22.85	47	8.8	23.19	45	7.8%	-0.16 [-0.57, 0.25]	<del>-+</del>
Vu et al., 2012	0.29	0.393	14	0.35	0.588	14	2.4%	-0.12 [-0.86, 0.63]	
Subtotal (95% CI)			61			59	10.2%	-0.15 [-0.51, 0.21]	•
Heterogeneity: Tau² = 0.00; Test for overall effect: Z = 0.			1 (P =	0.92); l²	= 0%				
.14.3 Telerehabilitation									
hen et al., 2017	11.8	7.95	26	11.78	8	24	4.2%	0.00 [-0.55, 0.56]	<del></del>
in et al., 2014	5	8.8	11	2.9	4.63	12	1.9%	0.29 [-0.53, 1.12]	<del></del>
lijenhuis et al., 2016	_	21.77	9		15.24	10	1.6%	-0.18 [-1.09, 0.72]	
Subtotal (95% CI)	-0.57	21.77	46	5.23	13.24	46	7.8%	0.04 [-0.37, 0.45]	•
Heterogeneity: Tau² = 0.00; Test for overall effect: Z = 0.				0.74); l²	= 0%	40	.1070	[ 0107 ; 0140]	Ţ
otal (05% CI)			710			540	100.0%	0.001.003.0303	
Fotal (95% CI)	ONE O	107 40		- 0.00	. 12 - 00		100.0%	0.08 [-0.03, 0.20]	Ţ
leterogeneity: Tau² = 0.00; [est for overall effect: Z = 1. [est for subgroup difference	40 (P = 0	1.16)	·						-4 -2 0 2 Favours [control] Favours [experimental]


Supplementary Table XXXIV.—Forest-plot regarding the effect of new-technologies on activity in patients with chronic stroke when provided in addition vs in substitution of conventional therapy - virtual reality.

	-	eriment			ontrol	_		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.16.1 In addition									
Aprile et al., 2020	6.04	8.547	91	6.7	4.84	99	4.8%	-0.10 [-0.38, 0.19]	<del>-</del>
Askin et al., 2018	1.75	13.3	18	0	7.81	20	2.3%	0.16 [-0.48, 0.80]	<del></del>
Broeren et al., 2008	2.8	10	11	0.4	10.56	11	1.5%	0.22 [-0.61, 1.06]	<del></del>
Brunner et al., 2017	11.9	12.01	57	12.6	11.83	55	4.1%	-0.06 [-0.43, 0.31]	<del></del>
Chen et al., 2015 (a)	4.9	12	8	1.5	7.25	8	1.2%	0.32 [-0.66, 1.31]	<del></del>
Chen et al., 2015 (b)	3.1	13.12	8	1.5	7.25	8	1.2%	0.14 [-0.84, 1.12]	<del></del>
Choi et al., 2014	12.6	5.7	10	15.3	7.2	10	1.4%	-0.40 [-1.29, 0.49]	
		4.93	9		11.72	9			
Crosbie et al., 2012	0.6						1.3%	-0.24 [-1.17, 0.68]	
da Silva Cameirao et al., 2011	60.7	10.31	8	46.1	11.05	8	1.0%	1.29 [0.18, 2.40]	
Hung et al., 2019	0.085	0.41	17	0.07	0.72	16	2.1%	0.03 [-0.66, 0.71]	
Jo et al., 2012	8.5	7.7	15	2	3.29	14	1.7%	1.05 [0.27, 1.84]	<del></del>
≺im et al., 2011	9.4	16.25	15	9	12.17	13	1.8%	0.03 [-0.72, 0.77]	
<im 2012<="" al.,="" et="" td=""><td>1.5</td><td>10.51</td><td>10</td><td>0.28</td><td>5.06</td><td>10</td><td>1.4%</td><td>0.14 [-0.74, 1.02]</td><td><del></del></td></im>	1.5	10.51	10	0.28	5.06	10	1.4%	0.14 [-0.74, 1.02]	<del></del>
<im 2018<="" al.,="" et="" td=""><td>8.4</td><td>8.68</td><td>11</td><td>9.6</td><td>10.35</td><td>8</td><td>1.3%</td><td>-0.12 [-1.03, 0.79]</td><td></td></im>	8.4	8.68	11	9.6	10.35	8	1.3%	-0.12 [-1.03, 0.79]	
≺iper et al., 2011		14.59	40		12.63	40	3.4%	0.80 [0.34, 1.25]	_ <del>-</del>
iper et al., 2018		12.75	68		12.26	68	4.3%	0.36 [0.03, 0.70]	<u> </u>
Kong et al., 2016		12.73	33		11.76	34	3.2%	0.20 [-0.28, 0.68]	<del></del>
Kwon et al., 2012	24.69	14.9	13		10.07	13	1.7%	0.23 [-0.54, 1.01]	<u> </u>
_affont et al., 2020	15.7	16.3	25	7.4	12.2	26	2.7%	0.57 [0.01, 1.13]	
_ee et al., 2013	8.71	9.01	. 7	4.81	7.16	. 7	1.0%	0.45 [-0.62, 1.51]	<del></del>
_ee et al., 2016		10.47	13		10.48	13	1.7%	0.03 [-0.74, 0.80]	
Norouzi et al., 2019	0.2	14.66	9	-1.6	9.18	9	1.3%	0.14 [-0.79, 1.07]	<del></del>
Park et al., 2019	4.3	5.9	12	4.8	5.9	12	1.6%	-0.08 [-0.88, 0.72]	<del></del>
Rand et al., 2017	11.7	11.42	11	9	12.61	10	1.5%	0.22 [-0.64, 1.08]	<del></del>
Rogers et al., 2019	17.3	8.6	10	8.4	5.3	11	1.3%	1.21 [0.26, 2.16]	<del></del>
Saposnik et al., 2010	8.6	3.9	9	12	4.18	9	1.2%	-0.80 [-1.77, 0.17]	<del></del>
Shin et al., 2014	11.3	10.64	9	6.3	5.67	7	1.1%	0.53 [-0.48, 1.54]	
3hin et al., 2014 3hin et al., 2015									
	9.56	4.61	18	2.71	3.12	17	1.7%	1.69 [0.91, 2.48]	
Bin et al., 2013	9.56	4.61	18	2.71	3.12	17		Not estimable	
Thielbar et al., 2014	3.1	5.6	7	-3.5	8.01	7	1.0%	0.89 [-0.22, 2.01]	
Turkbey et al., 2017	13.7	7.53	10	4.78	7.88	9	1.2%	1.11 [0.12, 2.09]	
Turolla et al., 2013	7.6	12.42	263	6.9	12.99	113	5.5%	0.06 [-0.17, 0.28]	<del>-</del>
/illafane et al., 2018	22.8	2.4	16	21.6	2.4	16	2.0%	0.49 [-0.22, 1.19]	+
√in et al., 2014	18.37	20	11	17	21	12	1.6%	0.06 [-0.75, 0.88]	<del></del>
Zondervan et al., 2016	0.7	2.3	9	-0.6	2.9	8	1.2%	0.48 [-0.49, 1.44]	
Subtotal (95% CI)			881			730	67.3%	0.28 [0.13, 0.44]	•
Heterogeneity: Tau² = 0.07; Chi²	e 58.16.	df= 33	(P = 0.	004): l² :	= 43%				
Fest for overall effect: Z = 3.64 (									
		-,							
1.16.2 In substitution									
	4.0	0 22	-	6.5	10.2	2	0.60	-0.45 [-1.02.4.04]	
Bylietial., 2013 (a)	1.8	8.32	5	6.5	10.3	3	0.6%	-0.45 [-1.92, 1.01]	
Byl et al., 2013 (b)		11.25	5	6.5	10.3	3	0.6%	-0.53 [-2.01, 0.95]	
Duffetal., 2012	0.47	0.36	11	0.54	0.28	10	1.5%	-0.21 [-1.07, 0.65]	<del></del>
Givon et al., 2015	-0.3	14.64	20	8.3	14.75	21	2.3%	-0.57 [-1.20, 0.05]	<del></del>
Housman et al., 2009	0.1	0.4	15	0.1	0.7	16	2.0%	0.00 [-0.70, 0.70]	<del></del>
n et al., 2012	26.35	32.09	11	3.43	7.67	8	1.2%	0.87 [-0.09, 1.83]	+
Jang et al., 2005	4	4.84	5	-1.6	5.91	5	0.7%	0.94 [-0.41, 2.28]	<del>                                     </del>
Kang et al., 2009		13.54	8		11.92	8	1.1%	0.87 [-0.17, 1.91]	+
Kang et al., 2014		17.78	24		14.83	21	2.5%	0.46 [-0.13, 1.05]	<del> </del>
Kong et al., 2014	15	12.34	33		11.76	34	3.2%	0.20 [-0.28, 0.68]	<del></del>
			8						
Kottink et al., 2014	3.9	4.9		5	5.1	10	1.3%	-0.21 [-1.14, 0.72]	
_evin et al., 2012		17.28	6		12.83	6	0.9%	-0.16 [-1.29, 0.98]	T
Ogun et al., 2019	8.34	4.78	33	1.25		32		Not estimable	
Oh et al., 2019	3.4	4.9	17	3.5	7.2	14	2.0%	-0.02 [-0.72, 0.69]	
Piron et al., 2007	16.8	19.37	25	7.7	18.51	13	2.1%	0.47 [-0.21, 1.15]	+
Piron et al., 2010	5.6	7.22	27	4.7	9.07	20	2.6%	0.11 [-0.47, 0.69]	<del></del>
Saposnik et al., 2016	7.6	10.62	59	8.9	9.39	62	4.2%	-0.13 [-0.49, 0.23]	<del></del>
Schuster-Amft et al., 2018	24.37	15.2		20.17	21.5	32	2.8%	0.22 [-0.33, 0.76]	<del> </del>
Standen et al., 2017	3.17	8.34	9	1.17	3.69	9	1.3%	0.30 [-0.63, 1.23]	
Subtotal (95% CI)	3.17	0.34	310	1.17	5.08	295	32.7%	0.09 [-0.08, 0.26]	<b>L</b>
	- 43.05	46 4 7		443.17	400	233	JZ.1 70	0.03 [-0.00, 0.20]	T
Heterogeneity: Tau² = 0.00; Chi²			(P = 0.	41); l*=	4 %				
Test for overall effect: $Z = 1.04$ (	~ = u.30)								
Total (95% CI)			4404			4025	400.00	0.22 (0.40, 0.24)	_
			1191			1025	100.0%	0.22 [0.10, 0.34]	▼
Heterogeneity: Tau² = 0.05; Chi² Fest for overall effect: Z = 3.68 (I			(P = 0.	010); l²:	= 34%			_	-2 -1 0 1 2

# Supplementary Table XXXV.—Robot-assisted therapy.




# Supplementary Table XXXVI.—Telerehabilitation.




Supplementary Table XXXVII.—Forest-plot regarding the effect of new-technologies on activity in patients with subacute stroke according to the impairment severity - robot-assisted therapy.

Experimental					Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.33.1 Severe (UE-FN	//A: 0-15)								
Hesse et al., 2014	9.2	10.8	25	13	10.76	25	14.1%	-0.35 [-0.91, 0.21]	<del></del>
Rabadi et al., 2008	-0.59	7.33	10	3.94	3.2	10	11.4%	-0.77 [-1.68, 0.15]	<del></del>
Volpe et al., 2000 Subtotal (95% CI)	25	3.5	30 <b>65</b>	19.5	3.5	26 <b>61</b>	13.8% <b>39.3%</b>	1.55 [0.95, 2.15] <b>0.17 [-1.26, 1.59</b> ]	•
Heterogeneity: Tau <sup>2</sup> =	= 1.45; Ch	ni² = 28	i.82, df	= 2 (P <	0.0000	11); l²=	93%		
Test for overall effect:				- (		.,,			
1.33.2 Severe-Moder	rate (UE-	FMA: 1	5-34)						
Aisen et al., 1997	25.6	7.23	10	25.7	12.25	10	11.7%	-0.01 [-0.89, 0.87]	+
Dehem et al., 2019	6.5	9.14	15	3.1	7.26	17	13.0%	0.40 [-0.30, 1.11]	<del> -</del>
Lum et al., 2006	3.1	1.4	10	3.2	1.4	6	10.7%	-0.07 [-1.08, 0.94]	<del></del>
Masiero et al., 2007	32.76	7.2	17	25.5	10.5	18	13.1%	0.78 [0.09, 1.47]	<del></del>
Tomic et al., 2017	14.1	7.9	13	6.7	7.8	13	12.2%	0.91 [0.10, 1.73]	
Subtotal (95% CI)			65			64	60.7%	0.47 [0.11, 0.84]	<b>♦</b>
Heterogeneity: Tau² =				4 (P = I	0.38); I²	= 5%			
Test for overall effect:	Z= 2.54	(P = 0	.01)						
1.33.3 Moderate to N	Aild (UE-F	MA > 3	•						
Subtotal (95% CI)			0			0		Not estimable	
Heterogeneity: Not ap									
Test for overall effect:	Not app	licable							
Total (95% CI)			130			125	100.0%	0.34 [-0.22, 0.89]	<b>*</b>
Heterogeneity: Tau² =	= 0.49; Ch	ni <b>=</b> 31	.40, df	= 7 (P <	0.0001	); <b>I²</b> = 7	8%	ŀ	10 -5 0 5
Test for overall effect:	Z = 1.18	(P = 0	.24)					•	Favours [control] Favours [experimental]
Fest for subgroup diff	ferences	: Chi²=	0.17, (	df = 1 (P	= 0.68)	$  \mathbf{l}^2   = 0$	%		r around [contact] if around [experimental]


# Supplementary Table XXXVIII.—Virtual reality.




#### Supplementary Table XXXIX.—Telerehabilitation.




Supplementary Table XL.—Forest-plot regarding the effect of new-technologies on activity in patients with chronic stroke according to the impairment severity - robot-assisted therapy.




#### Supplementary Table XLI.—Virtual reality.




#### Supplementary Table XLII.—Telerehabilitation.




Supplementary Table XLIII.—Forest-plot regarding the effect of new-technologies on activity in patients with subacute stroke according to the treatment intensity – robot-assisted therapy.




#### Supplementary Table XLIV.—Virtual reality.




#### Supplementary Table XLV.—Telerehabilitation.



Supplementary Table XLVI.—Forest-plot regarding the effect of new-technologies on activity in patients with chronic stroke according to the treatment intensity - robot-assisted therapy.



#### Supplementary Table XLVII.—Virtual reality.



#### Supplementary Table XLVIII.—Telerehabilitation.

	Expe	eriment	al	Control				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.50.1 Less than 15 ho	ours of tr	eatmen	t						
Lin et al., 2014 Subtotal (95% CI)	5	8.8	11 0	2.9	4.63	12 <b>0</b>		Not estimable Not estimable	
Heterogeneity: Not app Test for overall effect: N		able							
1.50.2 More than 30 ho	ours of tr	eatmen	ıt						
Nijenhuis et al., 2016 Subtotal (95% CI)	-0.37	21.77	9 <b>0</b>	3.23	15.24	10 <b>0</b>		Not estimable Not estimable	
Heterogeneity: Not app Test for overall effect: N		able							
1.50.3 Between 15 and	d 30 hour	s of tre	atmen	t					
Subtotal (95% CI)			0			0		Not estimable	
Heterogeneity: Not app	licable								
Test for overall effect: N	lot applic	able							
Total (95% CI)			0			0		Not estimable	
Heterogeneity: Not app	licable							_	4 5 6 3 4
Test for overall effect: N	lot applic	able							-4 -2 U 2 4 Favours [control] Favours [experimental]
Test for subgroup diffe	rences: N	laga tok	icable						r avours (control) - ravours (experimental)